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 Abstract 
The activity of cyclin dependent kinases (CDKs), which are key regulators of the 
eukaryotic cell cycle, is regulated through post-translational mechanisms, including 
binding of a cyclin and phosphorylation.  Previously studies have shown that 
Leishmania mexicana CRK3 is an essential CDK that is a functional homologue of 
human CDK1.  In this study, recombinant histidine tagged L. mexicana CRK3 and the 
cyclin CYCA were combined in vitro to produce an active histone H1 kinase that was 
inhibited by the CDK inhibitors, flavopiridol and indirubin-3’-monoxime.  Protein 
kinase activity was observed in the absence of phosphorylation of the T-loop residue 
Thr178, but increased 5-fold upon phosphorylation by the CDK activating kinase 
Civ1 of Saccharomyces cerevisiae.  Seven recombinant L. major CRKs (1, 2, 3, 4, 6, 
7 and 8) were also expressed and purified, none of which were active as monomers. 
Moreover, only CRK3 was activated by CYCA and was phosphorylated by Civ1.  HA 
tagged CYCA expressed in L. major procyclic promastigotes was co-precipitated with 
CRK3 and exhibited histone H1 kinase activity.  These data indicate that in 
Leishmania CYCA interacts with CRK3 to form an active protein kinase, confirm the 
conservation of the regulatory mechanisms that control CDK activity in other 
eukaryotes, but identifies biochemical differences to human CDK1. 
 
1.  Introduction 
Despite recent advances in understanding of the cell biology of the protozoan parasite, 
Leishmania, its cell cycle remains relatively unexplored.  Fundamentally, the 
parasite’s cell cycle is the same as every other eukaryote’s featuring growth, DNA 
replication, mitosis and cytokinesis. In addition, Leishmania must ensure the 
duplication and faithful segregation of their singular organelles: the nucleus, the 
kinetoplast, the flagellum and the Golgi apparatus.  Leishmania possess orthologues 
of many of the protein kinases that have been shown to be key players in controlling 
the eukaryotic cell cycle, including cyclin-dependent kinases, Aurora and polo-like 
kinases [1-6], but direct evidence linking these orthologues to a role in Leishmania 
cell cycle control is limited [1,7]. In other eukaryotes, cyclin-dependent kinases 
(CDKs) act at the boundaries between different cell cycle stages, to prevent premature 
or inappropriate transition through key checkpoints.  Their activity is tightly regulated 
through a variety of mechanisms including binding of a cyclin partner and 
phosphorylation [8].  Cyclin binding is further regulated at the transcriptional level, 
resulting in cyclical expression, and post-translationally through targeted destruction 
by the proteasome [9].  There are two main sites of phosphorylation on CDKs:  close 
to the catalytic site, at Y15 and T14 (in human CDK1), and on the activation or T-
loop, at T161 (in human CDK1).  Phosphorylation of Y15 and T14 has an inhibitory 
effect [10,11] which can be reversed by dephosphorylation by the CDC25 
phosphatase [12].   Phosphorylation at the T-loop residue is required for the full 
activity of CDK1, CDK2 [13] and CDK4 [14] resulting in a dramatic conformational 
change in the T-loop, creating the substrate binding site and orientating ATP correctly 
for phospho-transfer [15].  However, CDK6 activity in vivo appears to be independent 
of its T-loop phosphorylation status [16].   
In mammalian cells, the kinase responsible for phosphorylating the T-loop threonine 
(CDK activating kinase or CAK) is itself a CDK (CDK7) that is found in a complex 
with cyclin H and an assembly factor, MAT1 [17].  In contrast, in budding yeast the 
CDK activating kinase consists of a single protein, known as CAK or Civ1 (CAK in 
vivo) [18].  Both can phosphorylate CDKs but they possess quite different substrate 
specificities:  Civ1 is predominantly cytoplasmic [19] and preferentially 
phosphorylates CDK monomers, whilst CDK7/cyclin H/MAT1 favours CDK/cyclin 
complexes [20].  In vitro, CDK7/cyclin H (with or without MAT1) can phosphorylate 
CDK1, CDK2, CDK3, CDK4 and CDK6 [14,21,22].  However, although T-loop 
phosphorylation of CDK4 is required for activity [14], CDK7 may not be responsible 
for this phosphorylation in vivo [16], implying that there may be more than one 
human CAK enzyme.  Saccharomyces cerevisiae, Civ1, can also phosphorylate and 
activate most mammalian CDKs in vitro [20,23,24], implying that the effect of the T-
loop phosphorylation in vitro is independent of the activating enzyme.   
In comparison with S. cerevisiae, Leishmania possess a relatively expanded repertoire 
of 12 cdc2-related kinases [5], perhaps reflecting the relative complexity of the 
parasite’s cell division cycle and the need to integrate that with the developmental life 
cycle, in which the parasite oscillates between proliferative and cell-cycle arrested 
forms.  CRK3 is the best described of the leishmanial CDKs.  It is highly conserved 
between different species of Leishmania (for example, there is only one amino acid 
difference between CRK3 of L. mexicana, L. major and L. donovani), complements a 
Schizosaccharomyces pombe cdc2 mutant [25] and functions at the G2/M boundary 
[7], suggesting it is a functional CDK1 homologue.  CRK3 is predicted to be 
regulated by similar mechanisms to other CDKs, since it possesses a conserved 
cyclin-binding domain and the three regulatory phosphorylation sites (Aligned to T14, 
Y15 and T160 of human CDK1) [2].  Eleven cyclins have been identified in the L. 
major genome and these fall into 3 classes based on their sequence characteristics [4]; 
mitotic cyclins (CYCA, CYC3, CYC6 and CYC8), PHO80-like cyclins (CYC2, 
CYC4, CYC5, CYC7, CYC10, CYC11) and transcriptional cyclins (CYC9).   All the 
cyclins are conserved with other trypanosomatids, such as Trypanosoma brucei, 
except CYCA, which appears to be specific to Leishmania species.   To date the only 
CDK:cyclin pair identified in Leishmania is the L. donovani CRK3:CYC1 (the 
syntenic homologue of L. major CYCA) [26].   
In the present work we successfully expressed, purified and reconstituted an active 
recombinant CRK3:CYCA protein kinase complex in vitro.  Recombinant 
CRK3:CYCA has histone H1 protein kinase activity in the absence of 
phosphorylation on the T-loop threonine, a feature that distinguishes it from 
mammalian CDK1.  Phosphorylation of the T-loop threonine by S. cerevisiae Civ1, 
however, is associated with a 5-fold increased kinase activity.  Thus these results 
confirm that the activity of the leishmanial CDK, CRK3, is regulated in a similar 
fashion to other eukaryotic CDKs, but that CRK3:CYCA has some differences from 
human CDK1 . 
2. Materials and methods 
2.1 Parasites 
L. major (MHOM/JL/80/Friedlin) and promastigotes were grown in modified Eagle’s 
medium with 10% (v/v) heat-inactivated foetal calf serum (designated complete 
HOMEM medium) at 25°C [27].  
2.2 Cloning Leishmania CRKs and CYCA 
N-terminally histidine tagged L. mexicana CRK3 was expressed from plasmid 
pGL751, which was constructed as follows:  CRK3 was PCR amplified using primers 
OL225 and OL894 (Table 1), which added Nde1 and Xho1 sites onto the 5’ and 3’ 
ends of the ORF respectively.  The PCR product was cloned into Nde1/Xho1 digested 
pET28a to create pGL751.  To make a non-tagged version, CRK3 was excised from 
pGL751 using NdeI/BamH1 and cloned into pET21a generating pGL1072. L. 
mexicana CYCA was amplified from genomic DNA with oligonucleotides primers 
OL813 and OL814 which added Nde1 and Xho1 sites onto the 5’ and 3’ end of the 
ORF respectively.  This was cloned into Nde1/Xho1 digested pET21a, to give plasmid 
pGL630, which encodes CYCA with a C-terminal six histidine tag. 
To generate histidine tagged L. major CRK3, PCR amplification of LmjF36.0550 was 
performed using L. major genomic DNA, oligonucleotides OL1787 and OL1788 and 
Invitrogen Thermozyme polymerase. The PCR product was subcloned into pET15b, 
which was pre-digested with BamHI and NdeI, generating pGL1340. L. major CRK1 
(LmjF21.1080; pGL1338), CRK2 (LmjF05.0550; pGL1339), CRK4 (LmjF16.0990; 
pGL1616), CRK6 (LmjF27.0560; pGL1341, CRK7 (LmjF26.0040; pGL1349), CRK8 
(LmjF11.0110; pGL1342) in combination with the oligonucleotides shown in Table 1 
were similarly PCR amplified and cloned into pET15b. 
To create HA epitope tagged L. mexicana CYCA , the gene was amplified with 
oligonucleotides incorporating the HA tag at the N or C-terminus (OL1937 and 
OL1938 and  OL1935 and OL1936 respectively) and cloned into the SmaI/BglII site 
of pXG [28]. 
To generate CRK3T178Ehis site directed mutagenesis was performed using 
manufacturers instructions (QuikChange kit, Stratagene) on plasmid pGL751 using 
oligonucleotide primers OL877 and OL878, resulting in plasmid pGL1071. 
2.3 Protein purification and kinase assays 
L. mexicana CRK3his was expressed in BL21 (DE3) pLysS Escherichia coli cells 
(Stratagene), inducing with 100μM IPTG at 20ºC overnight, and purified as described 
previously [2]. For L. mexicana CYCA, BL21 (DE3) pLYS E. coli cells were 
transformed with plasmid pGL630. Cells were induced for protein expression at 19oC 
over night using 5mM IPTG and CYCAhis was purified as described for CRK3his. 
Plasmids expressing L. major CRK1-CRK8 were transformed into BL21 (DE3) pLYS 
E. coli cells and induced with 1mM IPTG at 19oC over night. All the CRKs produced 
soluble protein, but expression levels varied from low (CRK6 and CRK8) to high 
(CRK1, CRK2, CRK3 and CRK7).  S. cerevisiae Civ1-GST was purified as described 
previously [24]. 
Protein kinase assays were performed as described previously [2]. Recombinant 
protein kinase was incubated in 50mM MOPS pH 7.2, 20mM MgCl2, 10mM EGTA, 
2mM DTT, 4μM ATP, plus 1µCi γ-P32ATP (3000Ci/mmol) and 2.5μg histone H1 per 
reaction. Reactions are incubated at 30oC for 30 min. Final volume of each reaction 
was 20 µl and at the end of the 30 min incubation 20 µl of 2 x Laemmli protein 
loading buffer was added to stop the reaction, samples then were incubated at 100oC 
for 5 min and loaded on 12% acrylamide gel. The gel was dried and exposed to 
KODAK sensitive film overnight.  
To assess the interaction of L. mexicana CRK3 with CYCAhis in vitro, BL21 DE3 E. 
coli cells were transformed with plasmid pGL630 to express CYCAhis.  Cell lysate 
was incubated with 200 µl of Ni-NTA agarose (Qiagen) bead slurry for 5 min at room 
temperature and centrifuged for 5 min at 2100g. This column of Ni-NTA + CYCAhis 
was washed 2 x with PBS 7.4 and incubated with a soluble bacteria lysate containing 
non tagged CRK3 for 30 min, mixing at room temperature to permit the binding of the 
two proteins. The beads were then centrifuged at 1000g for 5 min. The column was 
washed 2X with PBS 7.4 and eluted in 100 µl fractions with phosphate buffer 
consisting of 100mM NaPi 7.4, 10mM NaCl and 0.5M imidazole (pH 8.0). 10 µl of 
each elution fraction was mixed with 10 µl Laemmli protein loading buffer 2 x and 
the total volume of 20 µl was loaded on a 12% SDS-PAGE gel. The proteins on the 
gel were transferred to a PVDF membrane and a western blot was performed using α-
CRK3 antibodies [7] diluted 1:2000.  
2.4 Immunoprecipitation 
L. major were transformed with plasmids pGL1388 and pGL1389 using the method 
of Robinson and Beverley [29].  Transformants were selected in the presence of 50μg 
ml-1 G418. These cell lines were grown to mid log phase and 50ml of culture was 
harvested at 1000g for 10 min at 4oC.  The cell pellet was then washed twice in cold 
PBS and resuspended in 1ml of IP lysis buffer (50mM Tris pH 7.5, 150mM NaCl, 
0.1% Nonidet P40) containing protease inhibitors. To this lysis suspension, 50 µl of 
HA affinity purification matrix (Roche) was added and an overnight incubation at 4oC 
with agitation was done. The matrix was then washed 3X with 1ml of lysis buffer and 
resuspended in 50 µl of lysis buffer. 10 µl was loaded on an SDS-PAGE gel, which 
was used either for Western blotting or silver staining.  5 µl of matrix was used in a 
kinase assay using histone H1 as a substrate.  For western blots to detect HA tagged 
proteins, monoclonal mouse HRP conjugated antibody (Roche) was used diluted at 1 
in 500.  
3. Results: 
3.1 Leishmania CYCA binds and activates CRK3 in vitro 
Leishmania mexicana CRK3 and CYCA were histidine tagged, expressed and 
purified from Escherichia coli (Fig. 1A, lanes 1 and 2 respectively).  A construct 
expressing CRK3 without a histidine tag was also generated.  To investigate the 
interaction of CRK3 and CYCA, an in vitro binding assay was carried out whereby 
CYCAhis was bound onto a Ni-NTA column and then incubated with an E. coli cell 
lysate containing non tagged CRK3.  After washing to remove non-specifically bound 
proteins, CYCAhis was eluted from the column and the presence of co-eluting CRK3 
in the eluant was assessed by Western blotting with an anti-CRK3 antibody [2].  
CRK3 was found to bind immobilised CYCAhis (Fig. 1B, lane 1) but not control 
beads (lane 2), showing that L. mexicana CRK3 can interact with CYCA in vitro.  
Recombinant monomeric CRK3his had negligible histone H1 protein kinase activity 
(Fig. 1C, lane 1), but when increasing concentrations of CYCAhis were pre-incubated 
with a fixed concentration of CRK3his, escalating histone H1 kinase activity was 
detected (lanes 2-7).  No histone H1 kinase activity was detected with cyclin alone 
(lane 8).  Optimal CRK3his:CYCAhis protein kinase activity was detected when 
CRK3 and CYCA were mixed in an approximate 1:1 molar ratio (lane 6). 
Phosphorylation of the canonical threonine residue in the T-loop of CDKs can be 
mimicked by substitution of the Thr residue with a negatively charged Glu residue 
[30]. To test if this was also the case for CRK3, site directed mutagenesis was carried 
out on the conserved T-loop threonine residue (Thr 178) of CRK3his to produce 
CRK3T178Ehis.  Affinity purified CRK3T178Ehis (Figure 1A, lane 3) lacked histone H1 
kinase activity both in the absence (data not shown) and presence of CYCA (Figure 
1D, lane 2).  The results show that CYCAhis is able to activate CRK3his (Figure 1D, 
lane 1) but not CRK3T178Ehis (lane 2), indicating that the mutation abolishes histone 
H1 kinase activity. 
L. mexicana CRK3his affinity purified from the parasite has been shown to have 
histone H1 kinase activity and to be inhibited by a variety of CDK inhibitors [2,31]. 
Although it is not known how many cyclins bind and activate CRK3 or the Thr178 
phosphorylation status of CRK3 in vivo, the IC50 of CRK3 purified from L. mexicana 
promastigotes could be compared to the recombinant purified CRK3his:CYCAhis 
with two well established CDK inhibitors, flavopiridol [32] and indirubin-3′-
monoxime [33].  IC50 values of 25 nM for flavopiridol and 33 nM for indirubin-3’-
monoxime with CRK3his:CYCAhis were somewhat different from the IC50 values of 
100nM [7] and 1.35μM [31] respectively for CRK3his affinity purified from L. 
mexicana. 
The genome of Leishmania major contains over 170 protein kinase genes [5], but it 
has not been possible to identify using bioinformatics analysis which of these genes 
might encode a functional Leishmania CDK activating kinase (CAK).  For this reason 
we tested if the GST-tagged S. cerevisiae CAK (Civ1-GST) [18], expressed and 
purified from E. coli (Fig 2A, lower panel), would phosphorylate CRK3 on Thr178. 
The yeast Civ1-GST was able to phosphorylate recombinant CRK3his in a dose 
dependent manner (Fig. 2A, lanes 2-6, upper panel).  Civ1-GST did not auto-
phosphorylate (lane 7) or phosphorylate CRK3T178Ehis (lane 8) confirming that 
Thr178 in CRK3 was the site of phosphorylation.  In order to assess whether the 
phosphorylation of CRK3his Thr178 would increase its protein kinase activity, a time 
course was carried out where CYCAhis and CRK3his were incubated in the presence 
and absence of Civ1-GST and histone H1 kinase activity assessed (Figure 2B). A 5-
fold increase in phosphorylated histone H1 was observed after Thr178 
phosphorylation by Civ1-GST (compare histone H1 signal in lanes 5 and 10).   
The natural substrate for Civ1 in Saccharomyces cerevisiae is CDC28 [18]. The fact 
that Leishmania CRK3 can be phosphorylated by Civ1 indicates that the 
phosphorylation site is conserved between these two species (see Figure 2C) and 
implies that this phosphorylation may play a role in regulating CRK3 activity, as it 
does for CDC28 [18].  L. major has 12 CRKs and 10 of these have a conserved T-
loop Thr or Ser residue [4].  To assess if other CRKs could be phosphorylated by 
Civ1-GST, L. major CRKs 1-8 (Fig 2C) were cloned into pET15b and expressed and 
purified from E. coli (Figure 2D).  CRK5 was not included as it has been reclassified 
as a MOK-family MAP kinase and is unlikely to be cyclin-dependent [4].  L. major 
CRKs were chosen as the L. mexicana genome was unavailable for analysis at the 
time and the CRK family in that species was unknown.   Only L. major CRK3his was 
found to be phosphorylated by Civ1-GST (Figure 2D). The purified monomeric CRKs 
were tested for histone H1 kinase activity, but only CRK3 showed any activity 
(monomeric CRK3 displays a low level of H1 activity in the absence of cyclin, see 
lane 1, Fig 1C; data not shown for other CRKs).  These data show that yeast Civ1-
GST has specificity for CRK3, the Leishmania CRK with the highest homology to 
Civ1’s natural substrate, CDC28 (Figure 2C), and that other Leishmania CRKs are not 
active histone H1 kinases, when expressed as soluble monomeric proteins.  This does 
not, however, preclude their activation by a cognate cyclin partner(s), yet to be 
identified. 
3.2 An active CRK3:CYCA complex in L. major  
CYCA was amplified with a C- or N-terminal HA tag and cloned into an episomal 
expression vector pXG to generate pGL1388 (N-terminal HA tag; HA-CYCA), and 
pGL1389 (C-terminal HA tag; CYCA-HA). L. major promastigotes were transfected 
with each plasmid and cell lines resistant to G418 isolated (designated L. major 
[pXG-CYCA-HA], for C-terminal tag, and L. major [pXG-HA-CYCA], for the N-
terminal tag). The expression of both CYCA-HA (Figure 3A, lane 1) and HA-CYCA 
(lane 2) was detected in procyclic promastigote cell lysates at the predicted size of 35 
kDa, while no HA-tagged protein was detected in wild type cells (lane 3). 
An immuno-precipitation (IP) of L. major and L. major [pXG-HA-CYCA] was 
performed using a column of conjugated anti-HA antibody (Figure 3B). The proteins 
immunoprecipitated from cell lysates were separated on a silver-stained SDS-PAGE 
gel and a protein corresponding to the expected size of HA tagged CYCA was 
immuno-precipitated from L. major [pXG-HA-CYCA] (Figure 3B upper panel, lane 
1), but not wild type L. major (lane 2). CRK3 was detected with a CRK3-specific 
antibody in immuno-precipitates of L. major [pXG-HA-CYCA] (Figure 3B, lower 
panel, lane 1) but not of wild type L. major (lane 2), confirming that CRK3 interacts 
with CYCA in procyclic promastigotes.  The precipitated material was assayed for 
histone H1 kinase activity. Activity was detected in immuno-precipitates from L. 
major [pXG-HA-CYCA] (Figure 3C, lane 1), but not from wild type L. major (lane 
2).  These data show that CYCA interacts with CRK3 in vivo and forms an active 
histone H1 kinase. 
4.  Discussion 
The work presented here is the first to describe the production of a defined active 
recombinant CRK3 kinase complex and demonstrates that, although the leishmanial 
CDK shares some regulatory features with mammalian and yeast CDKs, there are also 
some important differences.  In this study, soluble CRK3 was expressed in bacteria, 
purified and found to possess negligible histone H1 kinase activity.  A putative cyclin, 
CYCA [4], was identified in L. mexicana and also expressed in bacteria.  The purified 
CYCA protein was found to bind and activate CRK3 in vitro in a dose-dependent 
manner, with optimal kinase activity occurring when the molar ratio of kinase to 
cyclin was 1:1.  The syntenic homologue of CYCA in L. donovani, LdCYC1, has 
previously been shown to bind LdCRK3 in vivo but could not activate bacterially 
expressed LdCRK3 in vitro [26], possibly as a result of the recombinant protein(s) 
being mis-folded and therefore inactive.   
Previously, active CRK3 enzyme was purified from leishmanial lysates [31], but the 
complex was uncharacterised in terms of the cyclin partner(s) and the phosphorylation 
status of the kinase subunit.  The ability to re-constitute active kinase complex 
entirely from bacterially expressed protein ensures that the enzyme preparation is 
clearly defined, consistent and reproducible.  The accurate biochemical 
characterisation of this complex may help to further elucidate the role(s) of CRK3 in 
Leishmania.  Indeed it has enabled us to scrutinise the role of phosphorylation of the 
T-loop threonine in the regulation of CRK3 protein kinase activity. 
Phosphorylation of the T-loop threonine in CDK1, CDK2 and CDK4 is required for 
full activation [13,14] and is associated with a dramatic increase in protein kinase 
activity [34].  This increased activity is explained by the conformational change 
elicited by phosphorylation, which creates the substrate binding site and orientates 
ATP for phospho-transfer [15,35].  Mutation of the T-loop threonine to glutamic acid 
is thought to mimic phosphorylation at this site and has been shown  to result in the 
activation of certain protein kinases that require T-loop phosphorylation, including a 
CDK from Plasmodium falciparum [30,36]. Mutation of the T-loop residue of CRK3 
to glutamic acid (CRK3T178E), however, did not activate the enzyme; instead it 
abolished protein kinase activity both in the absence and presence of CYCA.  This 
result is consistent with what is observed for other CDKs; the T-loop threonine is 
essential for catalytic activity in CDK1 [37], CDK2 [38] and S. cerevisiae CDC28 
[39].  Since this approach to mimic T-loop phosphorylation was unsuccessful and 
because the leishmanial CAK has not yet been identified, we further explored the 
requirement for CRK3 to be phosphorylated on its T-loop using the S. cerevisiae 
monomeric CAK, Civ1 [18]. 
The natural substrate for Civ1 is CDC28 but Civ1 can also phosphorylate and activate 
most mammalian CDKs in vitro [20,24].  Civ1 could phosphorylate wild type CRK3 
in vitro but not CRK3T178E, confirming T178 as the phosphorylation site in CRK3, as 
predicted.  Pre-incubation of the CRK3:CYCA complex with Civ1 resulted in 
phosphorylation of the kinase subunit and a 5-fold increase in its histone H1 kinase 
activity.  Compared to the 80-100-fold increase observed for CDK1 and CDK2 [34], 
this is a fairly modest stimulation of activity.  Possible reasons for this include:  In the 
experimental conditions used, Civ1 may not be able to fully phosphorylate CRK3 
because (a) the conditions are sub-optimal; the conditions used were those optimised 
for the subsequent phosphorylation of histone H1 by the CRK3 complex, (b) the 
sequence of the T-loop is only partially conserved (Fig 2C, CRK3 72% identical to 
CDC28) and CRK3 is a inefficient substrate for Civ1 or (c) because Civ1 prefers 
CDK monomer as its substrate and may not have been able to efficiently 
phosphorylate the CRK3:CYCA complex.  Indeed, it is known that Civ1 
phosphorylates monomer CDK2 much more efficiently than CDK2/cyclin A 
complexes [20] and the intensity of the phosphorylated CRK3 (CRK3 monomer in 
Fig 2A) appears greater than when Civ1 was pre-incubated with CRK3:CYCA 
complex (Fig 2B).  Future experiments will test the relative efficiency of CRK3 
phosphorylation and activation when CRK3 is pre-incubated with Civ1 and then 
allowed to associate with CYCA.   
However, the modest increase in CRK3 kinase activity upon phosphorylation by Civ1 
may simply reflect the fact that T-loop phosphorylation is less important in the 
regulation of CRK3 activity than it is for CDK1, CDK2 and CDK4.  Not all protein 
kinases are activated through phosphorylation of their T-loop; those that are include 
CDKs, MAPKs and cAPK.  Immediately adjacent to the conserved aspartate residue 
within their catalytic domain, these protein kinases invariably have an arginine 
residue (RD kinases).  Whilst all protein kinases that are activated by phosphorylation 
of their T-loop possess this RD motif, the reciprocal is not true; not all RD kinases 
require T-loop phosphorylation for activation.  CRK3 does possess this RD motif but 
it may fall into the latter category, along with CDK5 and CDK6, whose activity 
appears to be independent of their T-loop phosphorylation status [16].  Protein kinases 
that do not utilise T-loop phosphorylation can adopt an active conformation without 
this post-translational modification [40]. 
In some cases, T-loop phosphorylation is required for CDK/cyclin complex 
formation:  T-loop phosphorylation is a pre-requisite for CDK1/cyclin B complex 
formation in vivo but CDK2 can form complexes with cyclins in the absence of T-
loop phosphorylation [13].  CRK3 appears to be more like CDK2 in this regard since 
CRK3 can form active complexes with CYCA in the absence of T-loop 
phosphorylation.  However, based upon current results, it cannot be ruled out that 
phosphorylation of CRK3 before incubation with CYCA would increase the 
efficiency of complex formation and the observed kinase activity. 
In a recent analysis of the phosphoproteome of bloodstream form T. brucei, CRK3 
was found to be phosphorylated on T33 and Y34, sites that correspond to human 
CDK1 T14 and Y15 [41,42].   In humans phosphorylation of Y15 by the wee1 kinase 
is a negative regulator of protein kinase activity [43] and the presence of wee1 in both 
the trypanosome and Leishmania genomes would suggest that CRK3 is regulated by a 
similar mechanism.   In contrast, no phosphorylation was detected on T-loop 
threonine residue of T. brucei CRK3 [41] and no CAK-like protein kinases have been 
identified in either the trypanosome or Leishmania genomes [4,5].  Thus it is possible 
that the trypanosomatids have evolved alternative mechanisms to positively regulate 
CRK3 activity. 
In contrast to the phosphorylation and activation of CRK3 by Civ1, none of the other 
leishmanial CRKs could be phosphorylated by Civ1 in vitro.  This may simply reflect 
the fact that the sequence similarity across the T-loop between these CRKs and the 
natural Civ1 substrate is lower than for CRK3.  However, none of these CRKs 
displayed any histone H1 kinase activity as monomers either.   As the CRKs are likely 
to be cyclin-dependent [4,5], these are likely to have to bind their cognate cyclin 
partners and possibly also be phosphorylated by the leishmanial CAK before they can 
form an active kinase.  Future work will strive to identify the cyclin partners for the 
remaining leishmanial CRKs. 
In summary, this work reports that the leishmanial CDK, CRK3, can associate with 
and be activated by the cyclin, CYCA; that the T-loop threonine residue is essential 
for kinase activity and that T-loop phosphorylation by the yeast CAK, Civ1, can 
further increase kinase activity, in an analogous fashion to mammalian CDKs, albeit 
to a much lesser degree than mammalian CDKs.  These results demonstrate that the 
way in which CDK activity is controlled in other eukaryotes is conserved in 
Leishmania but that there may be significant differences in the relative importance of 
the different regulatory mechanisms in the parasite. 
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 Figure legends 
Figure 1. L. mexicana CRK3:CYCA (A) SDS PAGE of CRK3his (lane 1), 
CYCAhis (lane 2) and CRK3T178Ehis (lane 3) purified from E. coli and stained with 
Coomassie blue R-250. (B) CYCAhis binds CRK3.  Ni-NTA beads, with (lane 1) and 
without (lane 2) bound CYCAhis, were incubated with L. mexicana promastigote cell 
extracts, washed, eluted and the eluted protein subjected to Western blot analysis with 
α-CRK3 antibody. (C) Activation of CRK3:CYCA. Phosphorylation of histone H1 by 
L. mexicana CRK3:CYCA was performed by mixing increasing quantities of 
CYCAhis (0.5μg-3μg in 0.5μg increments from lanes 2-8) to a fixed amount of 
CRK3his (4μg, lanes 1-7) in an in vitro kinase assay buffer containing 2.5μg of 
histone H1 per reaction and γ-P32-ATP.  Phosphorylated histone H1 was detected 
following SDS-PAGE and autoradiography. (D) CRK3T178Ehis kinase assay. 4 ug of 
CRK3his (lane 1) or CRK3T178Ehis (lane 2) was incubated with 3ug of CYCAhis and 
histone H1 kinase activity assessed as in panel C.  H1; histone H1. 
 
Figure 2. Phosphorylation of CRK3 with a CDK-activating kinase. (A) Upper 
panel. Phosphorylation of CRK3his or CRK3T178Ehis by S. cerevisiae Civ1-GST. 
CRK3his (3μg, lanes 1-7) or CRK3T178Ehis (3μg, lane 8) were incubated with 
increasing concentrations of Civ1-GST (lanes 1, 0μg, lanes 2-6, 0.5μg increasing in 
0.5μg increments, lanes 7 and 8, 2.5μg) in the presence of γ-P32-ATP.  Phosphorylated 
CRK3his or CRK3T178Ehis was detected following SDS-PAGE and autoradiography. 
Lower panel.  Coomassie blue R-250 stained protein used in the assay. (B) Histone 
H1 kinase assay.  CRK3:CYCA complex (4μg) was preincubated with 0.5 μg Civ1-
GST (lanes 1-5) or control buffer (lanes 6-10) prior to addition of histone H1 
substrate.  Samples were taken at 5, 10, 15 and 20 mins and analysed by SDS-PAGE 
and autoradiography. (C) Sequence alignment of L. major CRK1-4, 6-8, S. cerevisiae 
CDC28, the natural substrate for Civ1, and human CDK2.  The T-loop residue is 
indicated (*) (D) Phosphorylation of L. major CRKs by Civ1-GST.  Left panel:  
purified recombinant histidine-tagged CRK proteins.  Right panel:  Phosphorylation 
by Civ1-GST.   
Figure 3. CRK3:CYCA in L. major (A) Western blot of L. major promastigote cell 
lysates probed with anti-HA antibody. Lane 1: L. major [pXG-CYCA-HA], Lane 2: L. 
major [pXG-HA-CYCA], Lane 3, wild type L. major (B) Upper panel: Silver stained 
SDS-PAGE gel of protein eluted from anti-HA antibody affinity column. Lower 
panel. Western blot with anti-CRK3 antibody.  Lane 1: L. major [pXG-HA-CYCA] 
Lane 2: wild type L. major.  (C) histone H1 kinase assay with immuno-precipitated 






 [1]  Mottram, J. C. and Grant, K. M. Leishmania mexicana p12cks1, a functional 
homologue of fission yeast p13suc1, associates with a stage-regulated histone 
H1 kinase. Biochem. J. 1996;316:833-839. 
 [2]  Grant, K. M., Hassan, P., Anderson, J. S. and Mottram, J. C. The crk3 gene of 
Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 
kinase that associates with p12cks1. J. Biol. Chem. 1998;273:10153-10159. 
 [3]  Siman-Tov, M. M., Ivens, A. C. and Jaffe, C. L. Identification and cloning of 
Lmairk, a member of the Aurora/Ipllp protein kinase family, from the human 
protozoan parasite Leishmania. Biochimica et Biophysica Acta: Gene 
Structure and Expression 2001;1519:241-245. 
 [4]  Naula, C., Parsons, M. and Mottram, J. C. Protein kinases as drug targets in 
trypanosomes and Leishmania. Biochimica et Biophysica Acta: Proteins and 
proteomics 2005;1754:151-159. 
 [5]  Parsons, M., Worthey, E. A., Ward, P. N. and Mottram, J. C. Comparative 
analysis of the kinomes of three pathogenic trypanosomatids; Leishmania 
major, Trypanosoma brucei and Trypanosoma cruzi. BMC. Genomics 
2005;6:127. 
 [6]  Mottram, J. C., McCready, B. P., Brown, K. P. and Grant, K. M. Gene 
disruptions indicate an essential function for the LmmCRK1 cdc2-related 
kinase of Leishmania mexicana. Mol. Microbiol. 1996;22:573-582. 
 [7]  Hassan, P., Fergusson, D., Grant, K. M. and Mottram, J. C. The CRK3 protein 
kinase is essential for cell cycle progression of Leishmania mexicana. Mol. 
Biochem. Parasitol. 2001;113:189-198. 
 [8]  Malumbres, M. and Barbacid, M. Mammalian cyclin-dependent kinases. 
Trends Biochem Sci 2005;30:630-641. 
 [9]  Fung, T. K. and Poon, R. Y. A roller coaster ride with the mitotic cyclins. 
Semin. Cell Dev. Biol 2005;16:335-342. 
 [10]  Parker, L. L. and Piwinica-Worms, H. Inactivation of the p34(cdc2)-cyclin-b 
complex by the human WEE1 tyrosine kinase. Science 1992;257:1955-1957. 
 [11]  Mueller, P. R., Coleman, T. R., Kumagai, A. and Dunphy, W. G. Myt1:  A 
membrane-associated inhibitory kinase that phosphorylates Cdc2 on both 
threonine-14 and tyrosine-15. Science 1995;270:86-90. 
 [12]  Nilsson, I. and Hoffmann, I. Cell cycle regulation by the Cdc25 phosphatase 
family. Prog. Cell Cycle Res. 2000;4:107-114. 
 [13]  Larochelle, S., Merrick, K. A., Terret, M. E., Wohlbold, L., Barboza, N. M., 
Zhang, C., Shokat, K. M., Jallepalli, P. V. and Fisher, R. P. Requirements for 
Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by 
chemical genetics in human cells. Mol Cell 2007;25:839-850. 
 [14]  Kato, J.-Y., Matsuoka, M., Strom, D. K. and Sherr, C. J. Regulation of cyclin 
D-dependent kinase 4 (cdk4) by cdk4- activating kinase. Mol. Cell. Biol. 
1994;14:2713-2721. 
 [15]  Bartova, I., Otyepka, M., Kriz, Z. and Koca, J. Activation and inhibition of 
cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study 
reveals the functional importance of the glycine-rich loop. Protein Sci 
2004;13:1449-1457. 
 [16]  Bockstaele, L., Bisteau, X., Paternot, S. and Roger, P. P. Differential 
regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that 
CDK4 might not be activated by CDK7, and design of a CDK6 activating 
mutation. Mol Cell Biol 2009;29:4188-4200. 
 [17]  Devault, A., Martinez, A. M., Fesquet, D., Labbé, J. C., Morin, N., Tassan, J. 
P., Nigg, E. A., Cavadore, J. C. and Dorée, M. MAT1 ('menage a trois') a new 
RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish 
and Xenopus CAK. EMBO J. 1995;14:5027-5036. 
 [18]  Thuret, J. Y., Valay, J. G., Faye, G. and Mann, C. Civ1 (CAK in vivo), a novel 
Cdk-activating kinase. Cell Cell 1996;86:565-576. 
 [19]  Kaldis, P., Pitluk, Z. W., Bany, I. A., Enke, D. A., Wagner, M., Winter, E. and 
Solomon, M. J. Localization and regulation of the cdk-activating kinase 
(Cak1p) from budding yeast. J. Cell Sci. 1998;111:3585-3596. 
 [20]  Kaldis, P., Russo, A. A., Chou, H. S., Pavletich, N. P. and Solomon, M. J. 
Human and yeast Cdk-activating kinases (CAKs) display distinct substrate 
specificities. Mol. Biol. Cell 1998;9:2545-2560. 
 [21]  Fesquet, D., Labbé, J.-C., Derancourt, J., Capony, J.-P., Galas, S., Girard, F., 
Lorca, T., Shuttleworth, J., Dorée, M. and Cavadore, J.-C. The MO15 gene 
encodes the catalytic subunit of a protein kinase that activates cdc2 and other 
cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its 
homologues. EMBO J. 1993;12:3111-3121. 
 [22]  Aprelikova, O., Xiong, Y. and Liu, E. T. Both p16 and p21 families of cyclin-
dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-
dependent kinases by the CDK-activating kinase. J. Biol. Chem. 
1995;270:18195-18197. 
 [23]  Foley, E., O'Farrell, P. H. and Sprenger, F. Rux is a cyclin-dependent kinase 
inhibitory (CKI) specific for mitotic cyclin-Cdk complexes. Curr. Biol. 
1999;9:1392-1402. 
 [24]  Brown, N. R., Noble, M. E., Lawrie, A. M., Morris, M. C., Tunnah, P., Divita, 
G., Johnson, L. N. and Endicott, J. A. Effects of phosphorylation of threonine 
160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 
1999;274:8746-8756. 
 [25]  Wang, Y. X., Dimitrov, K., Garrity, L. K., Sazer, S. and Beverley, S. M. 
Stage-specific activity of the Leishmania major CRK3 kinase and functional 
rescue of a Schizosaccharomyces pombe cdc2 mutant. Mol. Biochem. 
Parasitol. 1998;96:139-150. 
 [26]  Banerjee, S., Sen, A., Das, P. and Saha, P. Leishmania donovani cyclin 1 
(LdCyc1) forms a complex with cell cycle kinase subunit CRK3 (LdCRK3) 
and is possibly involved in S-phase-related activities. FEMS Microbiol Lett 
2006;256:75-82. 
 [27]  Besteiro, S., Tonn, D., Tetley, L., Coombs, G. H. and Mottram, J. C. The AP3 
adaptor is involved in the transport of membrane proteins to acidocalcisomes 
of Leishmania. J. Cell Sci. 2008;121:561-570. 
 [28]  LeBowitz, J. H., Coburn, C. M., McMahon-Pratt, D. and Beverley, S. M. 
Development of a stable Leishmania expression vector and application to the 
study of parasite surface-antigen genes. Proc. Natl. Acad. Sci. USA 
1990;87:9736-9740. 
 [29]  Robinson, K. A. and Beverley, S. M. Improvements in transfection efficiency 
and tests of RNA interference (RNAi) approaches in the protozoan parasite 
Leishmania. Mol. Biochem. Parasitol. 2003;128:217-228. 
 [30]  Levin, L. R. and Zoller, M. J. Association of catalytic and regulatory subunits 
of cyclic AMP-dependent protein kinase requires a negatively charged side 
group at a conserved threonine. Mol Cell Biol 1990;10:1066-1075. 
 [31]  Grant, K. M., Dunion, M. H., Yardley, V., Skaltsounis, A.-L., Marko, D., 
Eisenbrand, G., Croft, S. L., Meijer, L. and Mottram, J. C. Inhibitors of 
Leishmania mexicana CRK3 cyclin-dependent kinase:  chemical library screen 
and antileishmanial activity. Antimicrob. Agents Chem. 2004;48:3033-3042. 
 [32]  Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A. and Worland, P. J. 
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. 
Biochem. Biophys. Res. Commun. 1994;201:589-595. 
 [33]  Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, 
P., Leost, M., Damiens, E., Marie, D., Marko, D., Niederberger, E., Tang, W. 
C., Eisenbrand, G. and Meijer, L. Indirubin, the active constituent of a Chinese 
antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell 
Biology 1999;1:60-67. 
 [34]  Connell-Crowley, L., Solomon, M. J., Wei, N. and Harper, J. W. 
Phosphorylation independent activation of human cyclin-dependent kinase 2 
by cyclin A in vitro. Mol. Biol. Cell 1993;4:79-92. 
 [35]  Stevenson, L. M., Deal, M. S., Hagopian, J. C. and Lew, J. Activation 
mechanism of CDK2: role of cyclin binding versus phosphorylation. 
Biochemistry 2002;41:8528-8534. 
 [36]  Graeser, R., Franklin, R. M. and Kappes, B. Mechanism of activation of the 
cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol. Biochem. 
Parasitol. 1996;79:125-127. 
 [37]  Ducommun, B., Brambilla, P., Felix, M. A., Franza, B. R., Karsenti, E. and 
Draetta, G. Cdc2 phosphorylation is required for its interaction with cyclin. 
EMBO J. 1991;10:3311-3319. 
 [38]  Abbas, T., Jha, S., Sherman, N. E. and Dutta, A. Autocatalytic 
phosphorylation of CDK2 at the activating Thr160. Cell Cycle 2007;6:843-
852. 
 [39]  Cross, F. R. and Levine, K. Genetic analysis of the relationship between 
activation loop phosphorylation and cyclin binding in the activation of the 
Saccharomyces cerevisiae Cdc28p cyclin-dependent kinase. Genetics 
2000;154:1549-1559. 
 [40]  Nolen, B., Taylor, S. and Ghosh, G. Regulation of protein kinases; controlling 
activity through activation segment conformation. Mol Cell 2004;15:661-675. 
 [41]  Nett, I. R., Martin, D. M., Miranda-Saavedra, D., Lamont, D., Barber, J. D., 
Mehlert, A. and Ferguson, M. A. The phosphoproteome of bloodstream form 
Trypanosoma brucei, causative agent of African sleeping sickness. Mol Cell 
Proteomics 2009;8:1527-1538. 
 [42]  Nett, I. R., Davidson, L., Lamont, D. and Ferguson, M. A. Identification and 
specific localization of tyrosine-phosphorylated proteins in Trypanosoma 
brucei. Eukaryot. Cell 2009;8:617-626. 





Gene Destination vector Primer Primer sequence 5’ to 3’ 
L. mexicana CRK3 pET28a OL225 GAATTCCATATGTCTTCGTTTGGCCGTGTGA 
L. mexicana CRK3 pET28a OL894 CTCGAGCTACCAACGAAGGTCGCTGA 
L. mexicana CRK3 Mutagenesis primer OL877  CCCATGCACACCTACGAGCACGAGGTGGTTACG 
L. mexicana CRK3 Mutagenesis primer OL878  CGTAACCACCTCGTGCTCGTAGGTGTGCATGGG 
L. mexicana CYCA pET21a OL813 CATATGGCGGTCCCACTGCGAATG 
L. mexicana CYCA pET21a OL814 CTCGAGCGCAGAAGTTGAAATGAA 
L. major CRK1 pET15b OL1783 CCATATGACCAGCCGGTACGAGCGGCAGGAGAAGATC 
L. major CRK1 pET15b OL1784 CGGATCCCTAAAACTGGAGGCTAAAGTACGGGTG 
L. major CRK2 pET15b OL1785 CCATATGCGGAGCAGCGGCCCCACCCCAGCGC 
L. major CRK2 pET15b OL1786 CGGATCCTTACGACTGCTGCTGCTGCTGCTGCTG 
L. major CRK3 pET15b OL1787 CCATATGTCTTCGTTTGGCCGTGTTACCGCCC 
L. major CRK3 pET15b OL1788 CGGATCCCTACCAGCGAAGGTCACTGAACCACGGG 
L. major CRK4 pET15b OL1789 CCATATGTCGACGGCGGGTCGGTACAAGCACG 
L. major CRK4 pET15b OL1790 CGGATCCTCATAGCAAGTGGCAGGCCTCCATCGTC 
L. major CRK6 pET15b OL1791 CCATATGTCCGCGTCAGTGAACGACTTGGATG 
L. major CRK6 pET15b OL1792 CGGATCCCTACGCATCCTTCATAAAGGGGTGTTCC 
L. major CRK7 pET15b OL1793 CCATATGGACAAGTACGCGTTGGGGCCGGTTATC 
L. major CRK7 pET15b OL1794 CGGATCCTCATGCACGCAGCAAGGTATCTGAGAG 
L. major CRK8 pET15b OL1795 CCATATGGGAGGGGAACTGGATAACCAGAAC 
L. major CRK8 pET15b OL1796 CGGATCCTCAATGCTCCAGCTCCTTCCGCTTGACC 
L. mexicana CYCA pXG OL1935 CCC CGG GAT GGC GGT CCC ACT GCG AAT GAG GA 
L. mexicana CYCA pXG OL1936 TGG ATC CTC AGG CAT AGT CCG GGA CGT CGT AGG GGT 
L. mexicana CYCA pXG OL1937 CCC CGG GAT GTA CCC CTA CGA CGT CCC GGA CTA TGC 
L. mexicana CYCA pXG OL1938 GTG GAT CCT CAC GCA GAA GTT GAA ATG AAA GG 
Restriction endonuclease sites are underlined   
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